Published in the Journal of Allergy and Clinical Immunology, a study looking at the dosage of an experimental drug nemolizumab for the treatment of itchy skin in people with atopic dermatitis eczema and severe pruritus.
Researchers evaluated a new dosing strategy for the drug over a 24 week randomized double blind study that compared varying doses administered by injection versus placebo with concomitant use of topical corticosteroids.
The Findings: The drug lessened severity of itchiness and size of affected areas. Overall, nemolizumab made rapid and sustained improvement in patients with maximal efficacy observed at doses of 30 milligrams
Given that the dosing strategy for this drug is still in an experimental phase, how will you talk to your patients about trying it – or will you?